Some have gone off without a hitch, while others fell into serious scrutiny as mouthwatering financial figures were revealed and major technologies were acquired.
Here are the 10 biggest mergers and acquisitions in medtech in 2021:
Next>[Image from Jp Valery on Unsplash]
Across 2021, medtech has seen a wide range of mergers and acquisitions covering several areas of devices, pharmaceuticals and more.Some have gone off without a hitch, while others fell into serious scrutiny as mouthwatering financial figures were revealed and major technologies were acquired.
Here are the 10 biggest mergers and acquisitions in medtech in 2021:
Next>>
Philip Morris (NYSE:PM) announced today that its offer to buy inhaled drug delivery technology developer Vectura has become unconditional.
Having received valid acceptances for or acquired 74.77% of Vectura shares, in excess of the 50% required under the acceptance condition, along with confirming that all other conditions to the offer have been satisfied or waived, the deal reached unconditional status.
Get the full story at our sister site, Drug Delivery Business News.
The American Lung Association condemned the recently announced acquisition of Vectura by cigarette maker Philip Morris (NYSE:PM).
Earlier this month, Philip Morris announced that it agreed to acquire inhaled drug delivery technology developer Vectura for $1.2 billion.
In response to the acquisition, American Lung Association president & CEO Harold Wimmer and American Thoracic Society president Dr. Lynn Schnapp released a joint statement calling the purchase “the latest reprehensible choice from a company that has profited from addicting users to its deadly products.”
Get the full story at our sister site, Drug Delivery Business News.
Philip Morris (NYSE:PM) announced today that it agreed to acquire inhaled drug delivery technology developer Vectura for $1.2 billion.
New York-based Philip Morris agreed with the board of Vectura Group on the all-cash, recommended offer under which Vectura shareholders would be entitled to receive $2.07 per share (150 pence), representing a 46% premium to the ex-dividend closing price per Vectura share of $1.42 (103 pence) on May 25, 2021.
Get the full story at our sister site, Drug Delivery Business News.